Implementation of the Prostate Cancer Prevention Trial (PCPT).
The Prostate Cancer Prevention Trial is a randomized double blind chemoprevention trial of 18,882 men. It is designed to test the difference in the histologically proven prostate cancer prevalence between a group of participants given finasteride and another given placebo for 7 years. We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase.
Goodman
Phyllis J
PJ
Southwest Oncology Group Statistical Center, M/S M3-C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109-1024, USA. pgoodman@fhcrc.org
Tangen
Catherine M
CM
Crowley
John J
JJ
Carlin
Susan M
SM
Ryan
Anne
A
Coltman
Charles A
CA
Ford
Leslie G
LG
Thompson
Ian M
IM
D018890:Chemoprevention; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D018120:Finasteride / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000453:epidemiology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000706:statistics & numerical data; D012107:Research Design
D004791:Enzyme Inhibitors; D018120:Finasteride; D042944:Cholestenone 5 alpha-Reductase